We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Early Detection of Gut Microbiota Metabolite Linked to Atherosclerosis Could Revolutionize Diagnosis

By LabMedica International staff writers
Posted on 18 Jul 2025

Cardiovascular disease is the leading cause of death worldwide, and atherosclerosis plays a critical role in its development. More...

This chronic condition, characterized by the hardening and narrowing of arteries due to the accumulation of fat deposits and inflammation, poses challenges in early detection. Clinical practice currently focuses on factors like cholesterol, hypertension, and smoking, but diagnosing atherosclerosis in its early stages remains difficult.

The issue is compounded by the reliance on advanced imaging techniques, which are complex, expensive, and not always covered by public health systems. Researchers have now discovered that a specific metabolite in the blood, Imidazole propionate (ImP), is linked to the early stages of active atherosclerosis, providing a potential diagnostic marker for detecting the disease in individuals who otherwise appear healthy.

In a new study, researchers from the Centro Nacional de Investigaciones Cardiovasculares (CNIC, Madrid, Spain) showed that ImP, a metabolite produced by intestinal bacteria, is elevated in individuals with atherosclerosis. Through extensive research, it was found that ImP not only serves as a marker for the disease but also plays a causal role in its development. In animal models, the administration of ImP resulted in the formation of arterial plaques by activating the imidazoline receptor type 1 (I1R), which triggers systemic inflammation and promotes atherosclerosis.

The research team also discovered that blocking the I1R receptor in mice fed a high-cholesterol diet slowed the progression of the disease, opening up new possibilities for treatment. These findings suggest that targeting ImP and I1R could be an effective strategy in preventing or treating atherosclerosis. The findings, published in Nature, support early detection of this metabolite in blood as a new diagnostic tool and open the door to personalized treatment strategies. Researchers are now working on developing drugs that block the detrimental effects of ImP, which could be combined with cholesterol-lowering drugs for a synergistic effect.

“These findings open new possibilities for the early detection and personalized treatment of atherosclerosis,” said David Sancho, head of the CNIC Immunobiology Laboratory and lead author on the study. “Instead of focusing solely on cholesterol and other classic risk factors, we may soon be able to analyze blood for ImP as an early warning signal.”

Related Links:
CNIC


New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
New
Capillary Blood Collection Tube
IMPROMINI M3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: An innovative deep learning model can accurately predict MSI tumor and immune checkpoint inhibitor responsiveness (Photo courtesy of Jae-Ho Cheong/Yonsei University College of Medicine)

AI Model Accurately Predicts MSI Tumor and Immune Checkpoint Inhibitor Responsiveness

One in three people is expected to develop cancer in their lifetime, and a key factor in patient prognosis is the tumor’s microsatellite status—whether it is stable or shows microsatellite instability-high (MSI-H).... Read more

Industry

view channel
Image: The acquisition of Exosome Diagnostics adds the ExoDx Prostate test to Mdxhealth’s portfolio (Photo courtesy of Bio-Techne)

Bio-Techne Divests Exosome Diagnostics to Reposition Product Portfolio

Bio-Techne Corporation (Minneapolis, MN, USA) has entered into an agreement with Mdxhealth SA (Irvine, CA, USA), which will acquire its Exosome Diagnostics Inc. (Waltham, MA, US) business, including the... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.